New tezepelumab data shows improvements for severe asthma subgroup
TSLP blocker reduced exacerbations in patients with severe asthma and comorbid nasal polyps
Read More
Tag: Tezepelumab
AZ, Amgen’s asthma med tezepelumab gains FDA priority review
Priority review comes following positive results from the Phase III NAVIGATOR trial
Read More
AZ, Amgen’s SOURCE trial misses primary endpoint
New medicine tezepelumab is being studied in severe asthma
Read More
Amgen, AZ’s asthma drug tezepelumab scores phase III win
Detailed results are due to be presented at forthcoming medical meeting
Read More
AstraZeneca, Amgen’s tezepelumab wins ‘breakthrough’ status
AstraZeneca and Amgen’s tezepelumab has won breakthrough therapy status in the US for its potential to treat severe asthma without an eosinophilic phenotype.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
